Chemotherapy Induced Peripheral Neuropathy – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Chemotherapy Induced Peripheral Neuropathy – Pipeline Review, H1 2017’, provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy

– The report reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Chemotherapy Induced Peripheral Neuropathy therapeutics and enlists all their major and minor projects

– The report assesses Chemotherapy Induced Peripheral Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achelios Therapeutics Inc

Advinus Therapeutics Ltd

Apollo Endosurgery Inc

Aptinyx Inc

Asahi Kasei Pharma Corp

Can-Fite BioPharma Ltd

Celgene Corp

DermaXon LLC

Eisai Co Ltd

Immune Pharmaceuticals Inc

INSYS Therapeutics Inc

Kineta Inc

KPI Therapeutics Inc

Krenitsky Pharmaceuticals Inc

MAKScientific LLC

Metys Pharmaceuticals AG

Midatech Pharma US Inc

Mundipharma International Ltd

Nemus Bioscience Inc

Neurocentrx Pharma Ltd

Panacea Pharmaceuticals Inc

PeriphaGen Inc

PharmatrophiX Inc

PledPharma AB

Sova Pharmaceuticals Inc

Virobay Inc

WEX Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Chemotherapy Induced Peripheral Neuropathy Overview 8

Chemotherapy Induced Peripheral Neuropathy Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 16

Chemotherapy Induced Peripheral Neuropathy Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 20

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Chemotherapy Induced Peripheral Neuropathy Companies Involved in Therapeutics Development 27

Achelios Therapeutics Inc 27

Advinus Therapeutics Ltd 27

Apollo Endosurgery Inc 28

Aptinyx Inc 28

Asahi Kasei Pharma Corp 29

Can-Fite BioPharma Ltd 29

Celgene Corp 30

DermaXon LLC 30

Eisai Co Ltd 31

Immune Pharmaceuticals Inc 31

INSYS Therapeutics Inc 32

Kineta Inc 32

KPI Therapeutics Inc 33

Krenitsky Pharmaceuticals Inc 33

MAKScientific LLC 34

Metys Pharmaceuticals AG 34

Midatech Pharma US Inc 35

Mundipharma International Ltd 35

Nemus Bioscience Inc 36

Neurocentrx Pharma Ltd 36

Panacea Pharmaceuticals Inc 37

PeriphaGen Inc 37

PharmatrophiX Inc 38

PledPharma AB 38

Sova Pharmaceuticals Inc 39

Virobay Inc 39

WEX Pharmaceuticals Inc 40

Chemotherapy Induced Peripheral Neuropathy Drug Profiles 41

(amitriptyline + ketamine hydrochloride) Drug Profile 41

ACY-1083 Drug Profile 45

AM-1710 Drug Profile 46

APX-2009 Drug Profile 48

APX-3330 Drug Profile 49

BR-297 Drug Profile 52

cannabidiol Drug Profile 53

dimiracetam Drug Profile 56

Drugs for Peripheral Neuropathy Drug Profile 58

DX-0332 Drug Profile 59

E-2072 Drug Profile 60

HM-01 Drug Profile 61

KCP-400 Drug Profile 62

ketoprofen Drug Profile 63

KP-544 Drug Profile 64

KRN-5500 Drug Profile 65

LM-11A31BHS Drug Profile 69

Lpathomab Drug Profile 71

MR-309 Drug Profile 74

NB-2111 Drug Profile 76

NRX-2922 Drug Profile 77

NT-24336 Drug Profile 78

PAN-811 Drug Profile 79

PGN-503 Drug Profile 81

piclidenoson Drug Profile 82

pirenzepine hydrochloride Drug Profile 92

PP-095 Drug Profile 93

Q-201 Drug Profile 97

ricolinostat Drug Profile 98

Small Molecule to Inhibit Cystathionine Gamma Lyase for Inflammatory Pain and Chemotherapy Induced Peripheral Neuropathy Drug Profile 106

Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy Drug Profile 107

Small Molecules for Pain Drug Profile 108

Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy Drug Profile 109

Small Molecules to Block Nav

1.8 for Chemotherapy Induced Peripheral Neuropathy Drug Profile 110

Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders Drug Profile 111

Tetrodotoxin Drug Profile 112

thrombomodulin alfa Drug Profile 114

U-2902 Drug Profile 116

VBY-036 Drug Profile 118

XEN-106 Drug Profile 120

XT-150 Drug Profile 121

Chemotherapy Induced Peripheral Neuropathy Dormant Projects 122

Chemotherapy Induced Peripheral Neuropathy Discontinued Products 124

Chemotherapy Induced Peripheral Neuropathy Product Development Milestones 125

Featured News & Press Releases 125

Appendix 132

Methodology 132

Coverage 132

Secondary Research 132

Primary Research 132

Expert Panel Validation 132

Contact Us 132

Disclaimer 133

List of Tables

List of Tables

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Achelios Therapeutics Inc, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Advinus Therapeutics Ltd, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Apollo Endosurgery Inc, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Aptinyx Inc, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Asahi Kasei Pharma Corp, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Can-Fite BioPharma Ltd, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Celgene Corp, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by DermaXon LLC, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Eisai Co Ltd, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Immune Pharmaceuticals Inc, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by INSYS Therapeutics Inc, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Kineta Inc, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by KPI Therapeutics Inc, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Krenitsky Pharmaceuticals Inc, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by MAKScientific LLC, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Metys Pharmaceuticals AG, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Midatech Pharma US Inc, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Mundipharma International Ltd, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Nemus Bioscience Inc, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Neurocentrx Pharma Ltd, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Panacea Pharmaceuticals Inc, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by PeriphaGen Inc, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by PharmatrophiX Inc, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by PledPharma AB, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Sova Pharmaceuticals Inc, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by Virobay Inc, H1 2017

Chemotherapy Induced Peripheral Neuropathy Pipeline by WEX Pharmaceuticals Inc, H1 2017

Chemotherapy Induced Peripheral Neuropathy Dormant Projects, H1 2017

Chemotherapy Induced Peripheral Neuropathy Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports